Episode
Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki
- Podcast
- Cell & Gene: The Podcast
- Published
- Jan 1, 2026
- Duration seconds
- 1265
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/cell-gene-the-podcast-4048431/episodes/developing-itvisma-for-broad-range-treatment-of-sma-with-novartis-dr-norman-putzki/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/cell-gene-the-podcast-4048431/developing-itvisma-for-broad-range-treatment-of-sma-with-novartis-dr-norman-putzki.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA). Dr. Putzki walks us through the six-year development journey behind the STEER and STRENGTH Phase 3 programs. And we explore what the expanded age-rang...